SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Jul 18, 2018

SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: July 18, 2018 · CIK: 0001611746 · Accession: 0001213900-18-009346

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-225745

Date

July 18, 2018

Author

Very

Form

CORRESP

Company

SciSparc Ltd. (SPRC) (CIK 0001611746)

Letter

Via EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Irene Paik Re: Therapix Biosciences Ltd. Registration Statement on Form F-3 Filed June 20, 2018, as amended on July 17, 2018File No. 333-225745

Dear Ms. Paik:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Therapix Biosciences Ltd. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form F-3 be accelerated to Friday, July 20, 2018, at 10:30 a.m., Eastern Time, or as soon as thereafter practicable.

Any questions should be addressed to Jeffrey Schultz, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 692-6732.

Thank you very much.

Very
truly yours,
Therapix Biosciences Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Therapix
Biosciences Ltd.

4
Ariel Sharon Street

HaShahar
Tower, 16th Floor

Givatayim
5320047, Israel

	July
18, 2018

Via
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
      Irene Paik

      Erin
Jaskot

Re:  Therapix
Biosciences Ltd.

    Registration
                                         Statement on Form F-3

                                                                                Filed
                                         June 20, 2018, as amended on July 17, 2018File

                                                                                No.
                                         333-225745

Dear
Ms. Paik:

Pursuant
to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Therapix Biosciences Ltd. (the
“Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form F-3 be accelerated
to Friday, July 20, 2018, at 10:30 a.m., Eastern Time, or as soon as thereafter practicable.

Any
questions should be addressed to Jeffrey Schultz, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center,
666 Third Avenue, New York, New York 10017, telephone (212) 692-6732.

Thank
you very much.

    Very
truly yours,

    Therapix Biosciences Ltd.

     By:
    /s/Ascher Shmulewitz

    Ascher Shmulewitz

Chief Executive Officer

cc:	Jeffrey
Schultz, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

SecProbe.io